Literature DB >> 2320272

Syndrome of the posterior and anterior root in a late isolated CNS relapse of c-ALL. Case report.

E Baumgarten1, R Fengler, K Brockmeier, C Domeyer, U Schulte-Overberg, H J Schmid, D Scheffner, G Henze.   

Abstract

A 15 year-old girl who had c-ALL diagnosed in 1982 was presented in our clinic suffering from an ascended flaccid paresis and dysaesthesia of both legs. These are typical symptoms of polyradiculitis of the nerve roots L2-S2. A lumbal puncture revealed a pleocytosis with lymphoblasts which were up to 40% CD10 (cluster of differentiation) up to 70% CD19 and TdT (terminal transferase) positive. The diagnosis of late isolated CNS relapse was made. It is assumed that local residual infiltrations of leukemic cells into the nerve roots L2-S2 got into cell cycle and caused these rare CNS leukemia symptoms. Therefore the value of a craniospinal irradiation to prevent a CNS and systemic relapse is discussed.

Entities:  

Mesh:

Year:  1990        PMID: 2320272     DOI: 10.1007/bf00638898

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN: 0344-5607            Impact factor:   3.042


  4 in total

1.  The central nervous system in childhood leukemia. I. The arachnoid.

Authors:  R A Price; W W Johnson
Journal:  Cancer       Date:  1973-03       Impact factor: 6.860

2.  The BFM relapse studies in childhood ALL: concepts of two multicenter trials and results after 2 1/2 years.

Authors:  G Henze; S Buchmann; R Fengler; R Hartmann
Journal:  Haematol Blood Transfus       Date:  1987

3.  Proliferative kinetics of central nervous system (CNS) leukemia.

Authors:  A H Kuo; X Yataganas; J H Galicich; J Fried; B D Clarkson
Journal:  Cancer       Date:  1975-07       Impact factor: 6.860

4.  Comparison of maintenance treatment regimens for first central nervous system relapse in children with acute lymphocytic leukemia. A Pediatric Oncology Group study.

Authors:  V J Land; P R Thomas; J M Boyett; A S Glicksman; S Culbert; R P Castleberry; D H Berry; T Vats; G B Humphrey
Journal:  Cancer       Date:  1985-07-01       Impact factor: 6.860

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.